Publisher Correction: Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
Guardado en:
Autores principales: | Rebeca Santano, Diana Barrios, Fàtima Crispi, Francesca Crovetto, Marta Vidal, Jordi Chi, Luis Izquierdo, Eduard Gratacós, Gemma Moncunill, Carlota Dobaño |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/84346c4a6af34857b1f6084c3430ec74 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
por: Rebeca Santano, et al.
Publicado: (2021) -
An evaluation of commercial fluorescent bead-based luminex cytokine assays.
por: Joel Fleury Djoba Siawaya, et al.
Publicado: (2008) -
Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides
por: Charles Y. Tan, et al.
Publicado: (2018) -
Validation of a commercially available indirect ELISA using a nucleocapside recombinant protein for detection of Schmallenberg virus antibodies.
por: Emmanuel Bréard, et al.
Publicado: (2013) -
Comparison of commercial ELISA assays for quantification of corticosterone in serum
por: Anne Marie Kinn Rød, et al.
Publicado: (2017)